2
Jun

Genomic Markers in Prostate Cancer

Dr. Leonard Gomella, Chair of the department of Urology and the Director of the Sidney Kimmel Cancer Center Network, was recently interviewed by Targeted Oncology about four major genomic markers used to guide treatment decisions in prostate cancer. These four genomic markers help clinicians decide between active treatment for patients with prostate cancer or active …

9
May

Radiation Oncology Podcast Series: Insights in Head and Neck Cancer: Treatment Options and Associated Toxicities.

Dr. Adam Dicker Chairman of the Department of Radiation Oncology conducts the latest Radiation Oncology podcast with Otolaryngologist Dr.  Adam Luginbuhl Key Discussions: Interest in Head & Neck Cancer His passion to reduce the toxicities of treatment His current collaborative research efforts How we resemble each other! Check out the Podcast (Click Here)

4
May

Jefferson’s Buddy Program Gives Patients with Cancer Somebody to Lean On

                                                                                                                                                                                                                                                                                                                        Joe Lavalle, a Sidney Kimmel Cancer Center at Jefferson Buddy Program volunteer. The Sidney Kimmel Cancer Center at Jefferson Buddy Program matches patients diagnosed with prostate, breast and other types of cancer with survivors who have experienced the same or similar diagnoses, treatments and uncertainties. Their “survivor buddies” are cancer survivors ahead of them …

3
May

Dr. Leonard Gomella: “Blue light” cystoscopy for detection and treatment of non-muscle invasive bladder cancer

Dr. Leonard Gomella, MD In patients with non-muscle invasive bladder cancer, fluorescence cystoscopy can improve the detection and ablation of bladder tumors. In this paper we describe the technique and practical aspects of hexaminolevulinate (HAL) fluorescence cystoscopy, also known as “blue light cystoscopy”. Check out Dr. Gomella’s  Blue Light Video (Click Here)

27
Apr

Jefferson Harnessing “Big Data” to Broaden Cancer Research

With the help of internal and external collaborations, researchers in our Computational Medicine Center (CMC) at the Sidney Kimmel Medical College here at TJU are characterizing and analyzing the molecular drivers of several cancers, which may lead to more powerful diagnostics and personalized treatments that better target cancer’s root causes. The use of precision medicine …

26
Apr

Researchers Find Pathway that Could Make Abandoned Pancreatic Cancer Drug Effective Against the Disease

Our scientists have found that blocking one molecular pathway could make pancreatic cancer susceptible to formerly ineffective therapies. “While there’s more work to be done to confirm the results in pre-clinical models and then humans, we are encouraged by these preliminary results,” said Jonathan Brody, PhD, a researcher at our Sidney Kimmel Cancer Center and Director …

23
Apr

Dr. Gomella featured in Targeted Oncology

Experts Discuss Treatment Sequencing Strategies in CRPC As the treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) continues to evolve, optimal strategies are becoming more apparent on how to best sequence the multitude of novel therapies that have been approved in the past decade. To gain insight into current best practices and strategies …

21
Apr

Dr. Dicker featured in Oncology Times: The Role of Genomics in Prostate Cancer Care

Fertile Genomic Ground Leads to Growth of Technology, Knowledge Laberta, Valerie As medical oncology harvests the advantages of this fertile genomic age, so do the associated therapies that benefit cancer patients. Radiation oncology has sprouted some new opportunities for improved patient care and outcomes, now ripening with the help of technology and research. Adam Dicker, …

15
Apr

Reimagining Patient Engagement: Jefferson-Designed Application Helps Patients Make More-Informed Shared Medical Decisions

Making decisions about healthcare options can seem overwhelming to patients and their families, and, in many cases, patients are asked to make decisions even though they have a limited understanding of their options. The Decision Counseling Program (DCP) is an online software application that enables patients to make well-informed healthcare decisions together with their treating …

11
Apr

Brittany Simone awarded AACR Travel Grant from Taconic

  Taconic Celebrates Researchers Awarded AACR Travel Grant The AACR Annual Meeting is the premier meeting for cancer research. The 2016 meeting will be held April 16-20 in New Orleans, Louisiana, USA. The program includes sessions on precision checkpoint immunotherapy, CRISPR in drug discovery, CAR T cells, immunotherapy combination treatments, and much more. Taconic has provided four …

7
Apr

Radiation Oncology Podcast: Residency Program

Check out the latest Radiation Oncology podcast version 4 focusing on the Radiation Oncology residency program featuring : http://jdc.jefferson.edu/radoncjefferson/4/       Adam Dicker, MD, PhD Michael Hardin, MS, MPR2 Amy S. Harrison, MS Virginia Lockamy, PhD                     Emily Kremmel, MMP, MPR2 James Keller, PhD   …

4
Apr

Dr. Mitchell named to the Blue Ribbon Panel

Vice-President Biden’s National Cancer Moonshot Initiative Today, the National Cancer Institute (NCI), part of the National Institutes of Health, announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer Moonshot Initiative. The panel will serve …

1
Apr

Dr. Adam Dicker featured in OncologyNurseAdvisor

Radiotherapy/Histone Deacetylase Inhibitor Combination Safe, Effective in High-grade Gliomas Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas, according to a phase 1 clinical trial published in the Journal of Neuro-Oncology. The trial combined fractionated stereotactic re-irradiation therapy (FSRT) with panobinostat.1 “We saw synergy between radiotherapy and the …

Page 1 of 22